Context: Rapid developments in e-cigarettes, or electronic nicotine delivery systems (ENDS), and the evolution of the overall tobacco product marketplace warrant frequent evaluation of the published literature. The purpose of this article is to report updated findings from a comprehensive review of the published scientific literature on ENDS.
Conclusions: Studies indicate that ENDS are increasing in use, particularly among current smokers, pose substantially less harm to smokers than cigarettes, are being used to reduce/quit smoking, and are widely available. More longitudinal studies and controlled trials are needed to evaluate the impact of ENDS on population-level tobacco use and determine the health effects of longer-term vaping. CONTEXT E lectronic nicotine delivery systems (ENDS), or e-cigarettes, produce an inhaled aerosol instead of smoke, providing an alternative mode of nicotine delivery. [1] [2] [3] [4] [5] [6] The U.S. Food and Drug Administration's Center for Tobacco Products finalized a rule to regulate ENDS. 7 Thus, there is a pressing need to identify the pathways by which to manage ENDS and how to strike a balance between potential benefits and harms to public health. 4, 8, 9 Reviews have been published on ENDS in general [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] or on specific topics, including health effects; impact on smoking cessation; 29, [40] [41] [42] [43] 45, 47, 48, 51, [59] [60] [61] [62] [63] [64] [65] [66] [67] [68] [69] [70] [71] [72] [73] product features; 22, 39, [41] [42] [43] 45, 47, [74] [75] [76] [77] potential to induce dependence; 28, 45, 47, 78, 79 consumer perceptions; 26, 48, 80, 81 patterns of use; 8, 26, 43, 48, 51, [82] [83] [84] [85] [86] [87] [88] [89] [90] and policies. 8, 48, [91] [92] [93] [94] [95] [96] [97] [98] Two conducted a bibliometric review of the ENDS literature 86, 99 and 46% of the reviews were systematic. 11,13,15,16,22-28,33,34,36,39,46,48,53-58,60,61,66,68,70-75,79-82, 85,86,88-90,93,97,100-104 The dramatically changing product landscape warrants frequent updates and synthesis of the rapidly growing evidence to inform prudent practice, policy, and regulation. 9, 105, 106 This comprehensive review presents a current synthesis of empirical studies on ENDS across a broad range of topics.
EVIDENCE ACQUISITION
A systematic review of empirical articles on ENDS was conducted via a PubMed search through May 31, 2016 (Appendix Table 1 [available online] shows search strategy and eligibility criteria). Total number of articles combined across categories exceeds the total number of unique articles because many fit into multiple categories. ENDS, electronic nicotine delivery system. Categories 5 and 6 were added to the original protocol 107 to provide information. Study quality is not presented herein, but will appear in future papers. Figure 2 depicts the number of studies published each year. Appendix Table 2 (available online) details coding of articles.
Terminology
The inhalation of ENDS aerosol is referred to as "vaping," and the inhalation of the smoke from any combustible tobacco product as "smoking."
EVIDENCE SYNTHESIS
Of 1,634 articles identified through PubMed, 675 were included in the review (Figure 1 ). An additional twelve studies were included through targeted searches or discussion with experts.
Product Features
There were 75 studies of ENDS products, liquids, and emissions. 5, 6, Ten additional studies were published on methods to analyze ENDS liquids and vapor. [181] [182] [183] [184] [185] [186] [187] [188] [189] [190] One study measured hazardous waste potential of ENDS disposal. 191 Product performance and design. Products comprise a cartridge, heating element, and battery. 6, 112, 156, 192, 193 ENDS are available in three main subtypes: disposable "cigalike," rechargeable "cigalike," and rechargeable vaporizers (tank or open systems). Larger ENDS devices (i.e., tank/modified) can produce blood nicotine concentrations approaching those of cigarettes, but with a slower absorption rate; higher blood nicotine levels are more common among experienced vapers. 145, [192] [193] [194] [195] [196] [197] Liquid/vapor analysis. Mainstream and exhaled ENDS vapor contains ultrafine and fine particulate matter at similar sizes to that of smoke. 108,113,121,132,139-142, 148-151,162,163 Some studies found that the amount of particulate matter produced by ENDS is significantly lower than that found in smoke, 113 ,144,148,149 whereas others found no difference or slightly higher concentrations in ENDS. 121, 132, 142, 163 Because the chemicals in vapor particles differ substantially from those in smoke, it is unclear what these results about size and volume of particulate matter imply about relative harm of ENDS vapor versus smoke.
The ENDS nicotine content in liquid and vapor varies across manufacturers, devices, cartridges, and puff to puff. [110] [111] [112] [113] [114] [115] [116] 122, 124, 126, 128, 129, 138, 143, 147, 153, 159, 160, 183, 184 Mainstream and exhaled ENDS vapor contains nicotine 113, 148, 150, 151 generally at lower levels than in smoke, 113, 124, 136, 144, 157 or at a level comparable to smoking a low-nicotine cigarette. 122 One study suggested nicotine may be detected on surfaces in the home of vapers, 127 but another study found no difference in deposited nicotine on surfaces between homes with vapers and homes without smokers. 109 Liquids, mainstream, and exhaled ENDS vapor can contain propylene glycol, 111, 122, 125, 130, 133, 148, 150, 151, 184 vegetable glycerin, additives, and flavorings.
148,150,151,155
Although several potentially toxic constituents have been measured in some ENDS liquid and vapor, including tobacco-specific nitrosamines, heavy metals, and carbonyls (i.e., formaldehyde, acrolein, aldehydes), there are much fewer total constituents at much lower or trace levels when ENDS are used as intended, in non-"dry puff" conditions, than levels observed in smoke. 111,113,117- Summary. There is wide variability in nicotine delivery by ENDS brand, product type, and user profile. 112, 126, 153, 159 The amount of particulate matter and the chemical composition of vapor are unclear in terms of harms. Some liquids and vapor contain some potentially toxic constituents, but in far fewer numbers and at much lower or trace levels than found in smoke.
Health Effects
There have been 116 articles that examine the impact of vaping on human health 142, 150, 162, 169, 193, 195, and 13 on animal health. 243, [306] [307] [308] [309] [310] [311] [312] [313] [314] [315] [316] [317] Studies address physiologic and cognitive effects of vaping, adverse events associated with vaping, exposure to secondhand vapor, and cytotoxicity of ENDS. Specific human biomarkers measured are listed in Table 1 . Physiologic and cognitive effects. Human exposure to some potentially harmful chemicals is significantly lower for ENDS than for cigarettes. Laboratory studies find modest increases in nicotine biomarkers after 
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www.ajpmonline.org vaping. 169, 195, 197, 203, 206, [209] [210] [211] 215, 222, 223, 232, 233, 239, 246 The Food and Drug Administration received 35 adverse event reports (respiratory symptoms, eye irritation, headache, nausea, sore throat/irritation, dizziness, racing/irregular heart rate) of passive vapor exposure between January 2012 and December 2014. 258 Other studies report the most common adverse events associated with vaping as mouth and throat irritation, nausea, headache, and dry cough. 193, 199, 202, 203, 214, 217, 232, 240, 249, 264, 265, 288, 303, 304, 320 From 2012 to 2015, there were 92 reported overheating/fire/explosion events in the U.S., and about half resulted in injuries (i.e., thermal burns, lacerations, or smoke inhalation).
291
Secondhand electronic nicotine delivery system vapor exposure. Three studies have examined the individual health effects among non-smokers/vapers of exposure to secondhand ENDS vapor, one with machine-generated vapor 215, 216 and two via human-generated vapor.
169,236
Two studies found no difference in cotinine levels following vapor and smoke exposures, 215,236 whereas one study found nicotine content present in oral fluid from those exposed to vapor was much lower than from those exposed to smoke. 169 One study found no differences in pulmonary function following vapor and smoke exposure, 215 but white blood cell count, granulocyte count, and lymphocyte count increased significantly following smoke exposure, whereas vapor exposure did not affect complete blood count. 216 Secondhand vapor studies to date show that non-users may be exposed to nicotine in ENDS vapor but the level of exposure is low, and exposure to other compounds also appears very low, or at trace or non-detectable levels when compared with secondhand smoke. It is unclear if any levels are sufficient to be of biological concern to humans. More-definitive studies are needed before conclusions about harm can be made.
321,322
Cytotoxicity. In cellular studies, exposure to ENDS vapor increased anti-inflammatory processes, 275, 278 placed oxidative stress on exposed cells, 269, 279, 294, 301 and increased cell apoptosis and necrosis.
305 Particular ENDS flavors are more cytotoxic than others, but generally most studied ENDS liquids are much less cytotoxic than cigarette smoke extract. 213, 228, 238, 250, 254, 260, 295, 296, 308 In cytotoxicity studies, cinnamon flavor in ENDS was found to be the most toxic (i.e., inhibiting cell survival or inducing cell stress/ morphologic change) when comparing flavors.
198,247
Most studies find that nicotine levels are not correlated with cytotoxicity. 198, 213, 238, 255, 260, 312 Two studies examined the effect of vegetable glycerin and propylene glycol, frequently found in e-liquids, on various human and animal cells and found that they were not cytotoxic for any cell type.
198,297
Animal models. Studies performed in animal models show that exposure to ENDS may have some physiologic effects (i.e., reduced weight, oxidative stress, neurobiological changes), 243, 306, 310, 312 -317 yet these effects are less substantial than those caused by exposure to cigarettes. 243, 307, 310, [312] [313] [314] [315] [316] [317] Attempts to generalize from animal to human effects are premature without further research on human samples. Summary. Studies on the health effects of vaping indicate no or minimal impact on physiologic biomarkers and some possible acute positive effects on cognition and mood regulation. Adverse events reported by vapers are generally mild and resolve, though there have been serious adverse events reported in some cases. There have been a greater number of poison control center calls related to nicotine exposures from ENDS in recent years, including exposures among children. Calls related to cigarette exposures-where smoking is much more prevalent than vaping-remain more common. Secondhand vape studies show that non-users may be exposed to nicotine in vapor, but at lower levels than when exposed to smoke. Users also report using ENDS because they are less expensive than cigarettes, 145, 194, 332, 337, 338, 341, 350, 353, 358, 372, 389, 395, 455, 456, 459, 472, 502 for relapse prevention, 194, 353, 372 out of curiosity, 341, 347, 350, 358, 421, 422, 432, 434, 441, 444, 456, 461, 476 because they are accessible and convenient, 341, 366, 387, 477 for social reasons, 341, 347, 363, 387, 434, 444, 461, 502, 504 and because they taste 337, 358, 426, 472, 477, 496 or smell better than cigarettes. 341, 353, 389, 459, 461 Flavors are viewed as an attractive characteristic of ENDS, 345, 433 and are a cited reason for vaping. 332, 341, 350, 456, 466, 477 Summary. Awareness of ENDS is high, and most users report using them to aid in smoking cessation, to evade smokefree policies, or because they are perceived as less harmful. Beliefs that ENDS are less harmful than cigarettes have lessened over time.
Consumer Perceptions

Patterns of Use
Two hundred fifty articles 153, [192] [193] [194] 197, 203 640, 648 The 2014 National Health Interview Survey showed that ever use of ENDS among young adults aged 18-24 years in the U.S. in 2014 was 21.6%, whereas "every day" or "some days" use in the same age group was 5.1%. 610, 639 These data also show that ever use and "some days" or "every day" use of ENDS among all adults was 12.6% and 3.7%, respectively, in 2014. 610, 639 Although young adults were significantly more likely to report ever use of ENDS than older adults, they were not more likely than older adults to be using ENDS "some days" or "every day." 610 Use of ENDS varies by smoking status, with the majority of users being current smokers, followed by former smokers; never smokers are least likely to have tried ENDS. 323,333,336-339,342,344,346,348,350,351,354-357, 359,361,369,380,381,384,395,396,421,455,461,472,504,527,531,541,543,551, 552,561,568,575,577-579,582,584,590 National Health Interview Survey data show that recent former smokers (quit o1 year ago) were more likely to report using ENDS "every day" or "some days" (22.0%) than adults who had never smoked (0.4%); former smokers who had quit for Z1 year (2.3%); or former smokers who quit cigarettes Z4 years ago (0.8%). 610 Frequency of electronic nicotine delivery system use. There are an increasing number of studies characterizing frequency of ENDS use, with most studies indicating ENDS are used infrequently (i.e., 1-2 days per month or "rarely") by the majority of users, 335, 350, 381, 395, 507, 590, 593, 601, 643 and more frequent (e.g., daily) use is higher among recent quitters 395, 610 and current smokers. 326, 335, 374, 395, 404, 422, 514, 536, 541, 569 According to National Health Interview Survey data, recent quitters (o1 year) were four times more likely to be daily ENDS users than current smokers (13% vs 3.5%). 610 In 2014, the National Youth Tobacco Survey added measures of frequency of use in the past 30 days and found that of the 13.4% of high school students reporting any past 30-day ENDS use, 45.4% (or 6.1% of the population) had tried ENDS on 1-2 days; 16.2% (2.2% of the population) on 3-5 days; 12.0% (1.6% of the population) on 6-9 days; 10.9% (1.5% of the population) on 10-19 days; 5.8% (0.8% of the population) on 20-29 days; and 9.7% (1.3% of the population) used ENDS all 30 days. 510, 633 Of the 3.9% of middle school students reporting past 30-day ENDS use, more than half (54.5%, or 2.1% of the population) had used ENDS on 1-2 days. 510, 633 Topography. Ten studies examined ENDS user topography. 153, 197, 239, 271, 513, 538, 556, 564, 580, 583 Puff duration 197, 538 and volume 197,239 are higher for ENDS products than for cigarettes, but flow rate 197 (among experienced vapers) and puff counts 239 (upon initial use in naïve vapers) have been found to be lower than for cigarettes. Higher liquid nicotine concentration has been associated with shorter puffs, 271,564 but puff velocity shows no effect on nicotine yield. 153 There is significant intersubject variability in puff behavior, 583 suggesting that more research is needed to determine the impact of user topography on vapor production and nicotine intake. Summary. Because ENDS is a new and potentially disruptive technology, 4 it is expected that ENDS use has increased in all age groups since their introduction and up until at least 2014. The rate of increase among youth has recently slowed or flattened in 2015. ENDS use is most common among current and recent former smokers, whereas prevalence is low among never smokers and long-term former smokers. Most past 30-day ENDS use among youth in the U.S. consists of use on 1-2 days in the past month. Daily ENDS users are most likely to be recent former smokers.
Potential to Induce Dependence
The potential of ENDS to induce dependence is considered to be primarily a function of the products' ability to quickly deliver a rapid and adequate dose of nicotine to the brain of the user, 652 but cigarette smoking is still the most rapid method of nicotine delivery. 652, 653 Twenty-eight studies have examined nicotine biomarkers resulting from vaping. [195] [196] [197] 199, 203, 206, 209, 211, 215, [221] [222] [223] 225, 232, 239, 246, 300, 303, 335, 529, 564, 580, 615, [654] [655] [656] [657] [658] Nicotine delivery is dependent on characteristics of ENDS devices and liquids, such as battery size, device type, propylene glycol/vegetable glycerin ratio, and nicotine liquid 580 in which plasma nicotine levels are significantly lower and reached a peak more slowly than that achieved with ten puffs from a cigarette. Recent assessments with secondgeneration devices demonstrate that a plasma nicotine concentration similar to that of cigarettes can be achieved after vaping, dependent upon the user's puff topography 197 or ENDS liquid nicotine concentration. 564, 580 Whether such levels are routinely achieved by most vapers is unclear.
The immediate reinforcing subjective effects of using a drug that are substantially but not solely a function of dose and speed of nicotine delivery also influence its ability to induce dependence and elicit repeated use. 652, 653 Twenty-four studies have examined the subjective effects of vaping. 193, [195] [196] [197] 199, 203, [206] [207] [208] [209] and increases ratings of satisfaction/pleasantness. 195, 197, 199, 222, 223, 225, 335 Though some smokers find ENDS less reinforcing 195 and satisfying than cigarettes, 239,344 second-generation devices are more satisfying than first-generation devices.
330
There is only one proposed measure of ENDS dependence 540, 662 ; however, studies have used many approaches to assessing ENDS dependence and drawing comparisons between products, such as adapting existing scales for cigarette or nicotine dependence or measuring perceived dependence. Approximately one third of former smokers who are daily vapers perceive their dependence on ENDS to be as strong or stronger than their previous dependence on cigarettes. 193, 360, 446, 663 These studies suggest that the current class of ENDS products may have significantly lower ability to induce dependence than cigarettes, but are capable of inducing some level of satisfaction and dependence, especially when using second-generation (e.g., tank or mod devices with adequate concentrations of nicotine e-liquid/juice).
Smoking Cessation
A key question regarding ENDS is their potential role in facilitating smoking abstinence or meaningful smoking reduction. Included study designs and outcomes relevant to smoking cessation and vaping are presented in Appendix Table 3 (available online) .
Four RCTs show that ENDS are effective in helping some adult smokers to quit or to reduce their cigarette consumption. 203, 654, [664] [665] [666] In the studies that assessed smoking cessation, rates of cessation in the ENDS study groups were similar to or higher than rates of cessation seen in previous clinical trials of nicotine-replacement therapy (NRT). 667 Some prospective studies with loosely defined comparison groups report that vaping may be associated with no change or negative correlations with cessation. 323, 393, 522, [668] [669] [670] [671] This stands in contrast to other studies with more-precise measures of how ENDS were used (e.g., duration of use, type of device, use specifically for cessation), which suggest that regular, more intensive vaping can facilitate quit attempts and cessation. 252 reporting negative correlations between those who tried ENDS and smoking cessation have serious limitations, including selection bias (e.g., smokers who quit by using ENDS were excluded from the sample); inadequate measures of exposure (e.g., ever use in one's lifetime) to test for a cessation indication; and confounders (e.g., smokers who have repeatedly failed to quit are more likely to try ENDS). 669, 683, 684 This is similar to studies of NRT and smoking cessation in which some observational studies showed negative correlations, 685, 686 whereas 480 RCTs of NRT show strong positive cessation effects. 687 Observational studies with more-robust measures of how ENDS were used (e.g., duration of use, type of device, use for cessation) suggest that ENDS can facilitate quit attempts and cessation. 514, 516, 548, 678 More research-especially independent, high-quality RCTs with appropriate measures and control groups-is needed to further determine whether and how ENDS can be an effective cigarette-cessation or -reduction aid.
Marketing and Communication
There have been 74 articles on the marketing and communication of ENDS products. 348, 357, 370, 403, 410, 424, 433, 438, 451, 471, 475, 477, 499, 506, 629, Among noncombustible tobacco products, ENDS advertisements are the most widely circulated. 700 Individuals aware of ENDS report the most common product exposures are through in-person communications, by seeing them at the point of sale, and through online and TV advertisements. 324, 357, 395, 471, 475, [718] [719] [720] 736, 743 Conventions provide manufacturers an opportunity to promote and introduce new products through free samples, celebrity appearances, and branded merchandise giveaways. 733, 747 ENDS are promoted heavily online 451, 696 through ENDS company-sponsored advertisements 698 and users' social media profiles, 424 348, 403, 713, 721 Exposure to industry and ingredient warnings is associated with lower odds of intent to purchase ENDS. 715, 735, 748 Several studies have reported the presence of interior and exterior ENDS advertisements at tobacco retail outlets, 703, 705, 706, 730 including one study which found that the ENDS advertisements featured flavored products at the eye level of children. 706 The total expenditure for ENDS advertisements across all media channels is increasing annually, 749, 750 with a 52% increase from 2013 to 2014. 725 Blu eCigs led in total advertisement expenditure until Altria's MarkTen entered the national market in 2014. 725 Online ENDS advertisements do not account for a large portion of this financial investment. 751 However, this expenditure information is outdated and there is no established method to assess true advertisement expenditures in the current media environment.
Commonly marketed as alternatives to cigarettes, 111, 709, [752] [753] [754] [755] [756] ENDS advertisements often make claims, such as being an effective smoking-cessation aid. 5, 111, 555, 710, 754 The most common claims advertise ENDS as a healthier alternative to cigarettes, 111, 433, 709, 710, 730, 754 and a way to circumvent smoking bans. 709, 752, 753, 755 Advertisements also highlight celebrity use to appeal to youth. 709, 754 Sales There have been 30 articles addressing the sales of ENDS products. 44, 398, 424, 438, 471, 472, 697, 702, 705, 716, 730, 731, [757] [758] [759] [760] [761] [762] [763] [764] [765] [766] [767] [768] [769] [770] [771] [772] [773] [774] [775] The ENDS market is expanding 701, 757 and accessible to consumers through Internet vendors 472, 730, 770, 772 and in most tobacco outlets. 472, 705, 730, 731, 759, 760 Field observations of tobacco retail outlets have found that more than half of tobacco retailers sell ENDS. 438, 730, 731, 763 One study found no significant relationship between retail availability and neighborhood demographics, 705 but another study indicated a greater likelihood of ENDS retailers in communities with higher median incomes. 759 One cross-sectional survey of adults found that frequent (weekly/daily) vapers were significantly more likely to purchase over the Internet than infrequent (monthly or less) vapers. 472 Studies 716,764,773 assessing online retailers found inadequate age verification methods, with one study reporting a 93.7% rate of successful youth purchases without age verification. 764 ENDS products can be sold at an estimated 200%-400% markup in vape shops. 697 Information is limited on the impact of pricing on ENDS sales, with one study indicating that vapers are two to three times more sensitive to price than smokers, 758 and several studies finding that ENDS are substitutes for cigarettes as cigarette prices increase. 762 797 and policies related to vaping on American transit systems. 798 Seven studies examined the impact of policies (e.g., smokefree indoor air laws) on interest, 799, 800 demand, 758, 801 or use of ENDS. 624, 802, 803 One study found that in the event of a menthol cigarette ban, 15.1% of menthol smokers would switch to menthol ENDS. 803 Four studies examined the impact of state-level ENDS policies 804, 805 and potential areas of ENDS regulation 748, 806, 807 on tobacco use, suggesting that a ban on ENDS may increase demand for cigarettes.
DISCUSSION
This review highlights several major findings. First, ENDS are a heterogeneous and evolving product category, with variation in physical factors that can influence vapor production (e.g., tank style, battery power, temperature). E-liquids contain various combinations of nicotine, flavors, and carriers. These factors affect nicotine delivery, appeal, and ease of product use and underscore the degree to which individual preferences may play a role in use patterns. Second, detectable levels of some potential toxicants have been found in ENDS liquids and vapor, but studies of actual human exposures are few. Although it is difficult to estimate the precise difference in harmful exposure of vaping compared to smoking, experts have concluded that ENDS are substantially less harmful than cigarettes 267 and toxicant exposures are derived both from far fewer chemicals and at much lower levels or trace levels, estimated to be one fourth to 1/95th those of cigarette smoke. 125, 237, 321, 322 Third, ENDS can produce mild adverse reactions (e.g., irritation, nausea) in some users; poisonings via misuse and unintended exposure have also been documented. 266 Fourth, as expected for a novel product, vaping 509, 510, [808] [809] [810] The majority of vaping in all age groups occurs among current smokers, and recent studies also show that the prevalence of daily vaping is very low in both youth and adults. 404, 610, 633 Fifth, RCTs and population-based studies with more-precise exposure measures show that ENDS are at least as effective as NRT in helping some smokers to quit or reduce their smoking 514, 516, 548, 610 and may reach more smokers at scale than NRT. 1, 321, 322 Finally, various ENDS policies (e.g., inclusion in smokefree indoor air) have been implemented in many jurisdictions, 780 but there has been little evaluation of the impact of these policies on behavior.
Limitations
A strength of this review is its synthesis of a broad range of study designs and outcomes related to ENDS. Limitations include that eligible studies were restricted to those that are peer reviewed, indexed in PubMed, and available in English language. The authors did not quantify the risk of bias of the evidence given the size and heterogeneity of the sample of included studies. Though bias is possible, the authors used a process for identifying studies categorized under multiple outcomes and regular team communication to reduce bias in data extraction. The summary of studies on patterns of ENDS use is limited to U.S. data; however, a manuscript is in progress to synthesize these studies in depth, including studies conducted in other countries and other topics relevant to vaping patterns (e.g., devices, flavors, and brands).
CONCLUSIONS
There are a number of factors to consider when synthesizing the results. First, ENDS products are highly variable. A standardized method is needed to characterize products with respect to nicotine and toxicant delivery and their potential harms, both relative to smoking and relative to no use (absolute harm). Second, the field lacks consistent definitions of types of users and patterns of use, which complicates the interpretation of research findings. Third, many studies have small sample or cell sizes and employ convenience samples, raising concerns about selection bias, unmeasured confounders, low statistical power, and limited generalizability to draw firm national public health or policy conclusions. Fourth, there exist gaps in the current evidence base, including longitudinal data and data on reasons for vaping and use trajectories (including polytobacco use and use of cessation aids) that may help to explain population impacts and changing trends. 8 Fifth, caution must be exercised when drawing conclusions from in vitro, or cellular, studies because effects on cells cannot be readily extrapolated to human harms. 
